KR20120049900A - 항원성 타우 펩타이드 및 이의 용도 - Google Patents

항원성 타우 펩타이드 및 이의 용도 Download PDF

Info

Publication number
KR20120049900A
KR20120049900A KR1020127005415A KR20127005415A KR20120049900A KR 20120049900 A KR20120049900 A KR 20120049900A KR 1020127005415 A KR1020127005415 A KR 1020127005415A KR 20127005415 A KR20127005415 A KR 20127005415A KR 20120049900 A KR20120049900 A KR 20120049900A
Authority
KR
South Korea
Prior art keywords
peptide
tau
antigenic
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020127005415A
Other languages
English (en)
Korean (ko)
Inventor
3세 조지 조셉 스미스
켄네스 넬슨 윌스
제프 시안카오 주
Original Assignee
화이자 백신스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 백신스 엘엘씨 filed Critical 화이자 백신스 엘엘씨
Publication of KR20120049900A publication Critical patent/KR20120049900A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127005415A 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도 Abandoned KR20120049900A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22986009P 2009-07-30 2009-07-30
US61/229,860 2009-07-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028550A Division KR20130127547A (ko) 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20120049900A true KR20120049900A (ko) 2012-05-17

Family

ID=42941871

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127005415A Abandoned KR20120049900A (ko) 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도
KR1020137028550A Ceased KR20130127547A (ko) 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137028550A Ceased KR20130127547A (ko) 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도

Country Status (17)

Country Link
US (1) US20110177109A1 (OSRAM)
EP (1) EP2459214A1 (OSRAM)
JP (1) JP2013500326A (OSRAM)
KR (2) KR20120049900A (OSRAM)
CN (1) CN102596236B (OSRAM)
AR (1) AR078085A1 (OSRAM)
AU (1) AU2010277254B2 (OSRAM)
CA (1) CA2768346A1 (OSRAM)
CO (1) CO6612199A2 (OSRAM)
IN (1) IN2012DN00446A (OSRAM)
MX (1) MX2012001194A (OSRAM)
NZ (2) NZ598356A (OSRAM)
PE (1) PE20120817A1 (OSRAM)
RU (2) RU2518291C2 (OSRAM)
SG (1) SG177637A1 (OSRAM)
TW (2) TW201436804A (OSRAM)
WO (1) WO2011013034A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160201A (en) 2008-12-09 2017-02-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EA032675B1 (ru) * 2009-06-10 2019-07-31 Нью-Йорк Юниверсити Способ и композиции для лечения болезни альцгеймера и других таупатий
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
US9304138B2 (en) * 2010-10-07 2016-04-05 Katholieke Universiteit Leuven Pharmaceutical composition
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
AR092779A1 (es) 2011-10-07 2015-05-06 Ac Immune Sa Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
NZ703423A (en) * 2012-07-03 2018-02-23 Univ Washington Antibodies to tau
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
US10195257B2 (en) * 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
WO2016007414A1 (en) 2014-07-08 2016-01-14 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
US20180050097A1 (en) * 2015-03-25 2018-02-22 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
JP6913078B2 (ja) 2015-08-13 2021-08-04 ニューヨーク・ユニバーシティ タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
AU2018355325B2 (en) 2017-10-25 2024-11-28 Ac Immune S.A. Compositions of phosphorylated tau peptides and uses thereof
CN119409835A (zh) * 2017-10-27 2025-02-11 联脑科学公司 Tau肽免疫原构建体
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
CN108314737B (zh) * 2018-01-25 2021-03-16 中国科学院过程工程研究所 一种重组蛋白及其制备方法和应用
CN110548135B (zh) * 2018-05-31 2023-06-06 长春百克生物科技股份公司 磷酸化多肽抗原疫苗及其制备方法和应用
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
WO2020073121A1 (en) * 2018-10-07 2020-04-16 The University Of British Columbia Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
BR112021015501A2 (pt) * 2019-02-08 2021-10-19 Prothena Biosciences Limited Anticorpos que reconhecem tau
MX2021009508A (es) 2019-02-08 2021-09-08 Ac Immune Sa Metodo para la administracion segura de una vacuna de peptido de tau fosforilado.
US20200291391A1 (en) * 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
AU2020262899A1 (en) 2019-04-24 2021-11-18 Ac Immune S.A. Heterologous administration of tau vaccines
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
CA3142040A1 (en) * 2019-05-27 2020-12-03 The University Of British Columbia Conformation-specific epitopes in tau, antibodies thereto and methods related thereof
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
US20230302127A1 (en) * 2020-08-07 2023-09-28 Othair Prothena Limited Tau vaccine for the treatment of alzheimer's disease
WO2022054795A1 (ja) * 2020-09-08 2022-03-17 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
MX2024003039A (es) * 2021-09-08 2024-04-19 Biocad Joint Stock Co Anticuerpo quimerico, biespecifico, bivalente que comprende un heterodimero basado en cmh o proteinas similares a cmh.
WO2023056369A1 (en) * 2021-09-29 2023-04-06 Janssen Pharmaceuticals, Inc. Method of safe administration of tau phosphopeptide conjugate
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
AU568067B2 (en) 1981-10-23 1987-12-17 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3525624A1 (de) 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg Insektizid wirksames mittel zur bekaempfung von textilschaedlingen
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
DE69233723T2 (de) * 1991-12-06 2009-02-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP0817854A2 (en) 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
PT1005368E (pt) 1997-03-10 2009-11-19 Coley Pharm Gmbh Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
DK1003850T3 (da) 1997-06-06 2009-09-07 Univ California Inhibitorer af DNA-immunstimulatorisk sekvensaktivitet
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
IL137766A0 (en) 1998-02-12 2001-10-31 Immune Complex Corp Strategically modified hepatitis b core proteins and their derivatives
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
NZ511113A (en) 1998-10-16 2002-09-27 Smithkline Beecham Biolog S Adjuvant systems containing an immunostimulant absorbed on to a metal salt particle and vaccines thereof
CA2347411C (en) 1998-10-21 2012-04-03 The Government Of The United States Of America Virus-like particles for the induction of autoantibodies
DE69929470T2 (de) 1998-11-05 2006-08-24 Powderject Vaccines, Inc., Madison Genkonstrukte für genimmunisierung
JP2010510960A (ja) 1998-11-30 2010-04-08 サイトス バイオテクノロジー アーゲー 抗原の順序付けられた分子提示、提示の方法、および使用
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
BRPI0009163B8 (pt) 1999-03-19 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica e vacina que a compreende
EP1187629B1 (en) 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CZ20021045A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pomocný prostředek
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
PT1268530E (pt) 2000-04-07 2006-12-29 Univ Leeds Proteínas de fusão do antigénio do core da hepatite b
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
ES2260235T3 (es) 2000-06-22 2006-11-01 Ucb Pharma Limited Modificacion del antigeno "core" de la hepatitis b.
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2003213168A1 (en) 2002-02-21 2003-12-19 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
JP4644488B2 (ja) * 2002-07-19 2011-03-02 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト アミロイドベータ１−６抗原アレイを含むワクチン組成物
CA2509484C (en) 2002-12-10 2012-03-20 Lorantis Ltd. Stabilized immunogenic hbc chimer particles
PL1701968T3 (pl) * 2003-12-17 2015-11-30 Wyeth Llc Koniugaty nośników z peptydami immunogennymi i sposoby ich wytwarzania
CA2572427A1 (en) 2004-07-18 2006-01-18 Heather L. Davis Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
CA2574090A1 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
RU2007117752A (ru) * 2004-10-13 2008-11-20 Аблинкс Н.В. (Be) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
ES2348312T3 (es) * 2006-04-13 2010-12-02 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna her-2/neu a base de múltiples péptidos.
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
EA032675B1 (ru) * 2009-06-10 2019-07-31 Нью-Йорк Юниверсити Способ и композиции для лечения болезни альцгеймера и других таупатий
FR3058624B1 (fr) 2016-11-15 2018-12-07 L'oreal Brosse pour l'application d'un produit sur les cils et/ou les sourcils

Also Published As

Publication number Publication date
TW201106968A (en) 2011-03-01
CO6612199A2 (es) 2013-02-01
CN102596236A (zh) 2012-07-18
SG177637A1 (en) 2012-03-29
RU2014112002A (ru) 2015-10-10
WO2011013034A1 (en) 2011-02-03
NZ598356A (en) 2014-06-27
AU2010277254B2 (en) 2015-05-07
IN2012DN00446A (OSRAM) 2015-05-15
TWI461209B (zh) 2014-11-21
EP2459214A1 (en) 2012-06-06
JP2013500326A (ja) 2013-01-07
US20110177109A1 (en) 2011-07-21
RU2012102701A (ru) 2013-09-10
AU2010277254A1 (en) 2012-02-09
MX2012001194A (es) 2012-03-07
PE20120817A1 (es) 2012-07-07
WO2011013034A4 (en) 2011-04-28
KR20130127547A (ko) 2013-11-22
NZ618391A (en) 2015-07-31
CN102596236B (zh) 2015-06-24
TW201436804A (zh) 2014-10-01
RU2518291C2 (ru) 2014-06-10
CA2768346A1 (en) 2011-02-03
AR078085A1 (es) 2011-10-12

Similar Documents

Publication Publication Date Title
AU2010277254B2 (en) Antigenic tau peptides and uses thereof
JP5964280B2 (ja) ＩｇＥＣＨ３ペプチドワクチン
AU2013204233B2 (en) IgE CH3 peptide vaccine
HK1173376A (en) Antigenic tau peptides and uses thereof
HK1163511B (en) Ige ch3 peptide vaccine

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20120229

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120229

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130829

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131029

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140328

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20141030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140328

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20130829

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20141030

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20140528

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20131029

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20150226

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150130

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20141030

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140528

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20140328

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20131029

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20130829

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150330

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150226

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20141030

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20161129

Appeal identifier: 2015101001742

Request date: 20150330

J301 Trial decision

Free format text: TRIAL NUMBER: 2015101001742; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150330

Effective date: 20161129

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20161129

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20150330

Decision date: 20161129

Appeal identifier: 2015101001742

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20161214

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20161208

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

PC1904 Unpaid initial registration fee